Abstract | Depression is highly common throughout the life course and dementia is common in late life. Depression has been linked with dementia, and growing evidence implies that the timing of depression may be important in defining the nature of this association. In particular, earlier-life depression (or depressive symptoms) has consistently been associated with a more than twofold increase in dementia risk. By contrast, studies of late-life depression and dementia risk have been conflicting; most support an association, yet the nature of this association (for example, if depression is a prodrome or consequence of, or risk factor for dementia) remains unclear. The likely biological mechanisms linking depression to dementia include vascular disease, alterations in glucocorticoid steroid levels and hippocampal atrophy, increased deposition of amyloid-β plaques, inflammatory changes, and deficits of nerve growth factors. Treatment strategies for depression could interfere with these pathways and alter the risk of dementia. Given the projected increase in dementia incidence in the coming decades, understanding whether treatment for depression alone, or combined with other regimens, improves cognition is of critical importance. In this Review, we summarize and analyze current evidence linking late-life and earlier-life depression and dementia, and discuss the primary underlying mechanisms and implications for treatment.
Introduction
Depression is common across the lifespan, with one in five individuals experiencing a depressive episode during their lifetime. 1 Dementia is also very common in late life with the risk of dementia doubling every 5 years after age 65 years, 2 increasing to almost 50% among those ≥90 years old. 3, 4 Depression and dementia may be related in several ways. Depressive symptoms often occur among patients with dementia, and depression may be a reaction to early cognitive deficits. Depression can impair cognitive function, which results in a 'pseudodementia' presentation. Finally, depression may be a risk factor for, or early symptom of, dementia.
Given the current and projected growth of the elderly population, 5 a better understanding of the link between depression and risk of dementia is important, especially for possible treatment and prevention. Several challenges to this understanding exist, however. Major depressive disorder is common among patients with dementia, occurring in up to 20% of patients with Alzheimer disease (AD) and up to 50% of patients with vascular dementia (VaD). [6] [7] [8] Disentangling which disorder came first can, therefore, be difficult. In addition, although depression and dementia are considered to be distinct clinical entities, they share some features in common, including: impairment in attention and working memory, changes in sleep patterns, and reduction of social and occupational functioning. 9 In fact, the concept of 'pseudodementia' highlights how the distinction between depression and dementia may be blurred. 10, 11 The inter-relationship of depression and dementia is, therefore, complex and, when co-occurring, the two entities may be indistinguishable, which complicates the ability to de termine the exact relationship between the two conditions.
In this article, we review current knowledge on latelife and earlier-life depression and the associated risk of develop ing dementia, as well as discussing the mechanisms that may underlie the link between depression and dementia. We primarily focus on the evidence suggesting that depression is a prodromal symptom of, or risk factor for, dementia and discuss potential implications for screening and treatment.
Depression and risk of dementia
Most previous studies have examined late-life (in those aged 60 years or older) depression or depressive symptoms and risk of dementia, while only a few studies have examined earlier-life (younger than aged 60 years) depression. Given the variable nature of depression onset, the high occurrence of depression in young adulthood and middle age, and the long preclinical period of dementia, studying earlier-life depression may offer an opportunity to determine if depression is a risk factor for dementia, years before the syndrome starts. On the other hand, a notable relationship between late-life depression and dementia might enable improved study of depression as part of the prodromal stage of dementia. As such, studies focusing on both earlier-life and late-life depression could provide complementary evidence. design, two were cross-sectional (Table 1) and two were meta-analyses (not shown in this table). Of the 12 prospective studies, six found evidence supporting a twofold to fivefold increased risk of dementia associated with latelife depression, [12] [13] [14] [15] [16] [17] another found that even one additional depressive symptom increased dementia risk by 20%, 18 three found evidence supporting an association between late-life depression and dementia (but only in specific subgroups, including men and higher education), [19] [20] [21] and two studies found no effect of depression on dementia risk. 22, 23 Of the two longitudinal studies that found no relationship between dementia and depression, one was underpowered because of a small number of study participants 22 and the other measured history of depression with only a selfadministered questionnaire, which could be susceptible to recall bias. 23 The longest longitudinal study on depression and dementia covered 17 years of follow-up and the study authors reported a 70% increased risk of developing dementia in individuals with depression, 12 suggesting that longer follow-up may enable better assessment of depression as a risk factor for dementia. However, the follow-up times and statistical significance of other studies were highly variable. For example, one study reported that a history of depression increased the risk of AD almost twofold at baseline and 2-year follow-up, but the association was not observed at 5-year follow-up. 13 By contrast, another study found statistically significant results at 5-year follow-up, 14 and a further study found no link between depression and dementia at 9-year follow-up. 22 These discrepancies might be explained by variations in sample sizes, measures, and frequency and severity of depression. In fact, severity of latelife depression has been found to be important to the risk of dementia, as shown by four longitudinal studies. [14] [15] [16] 18 The number of depressive symptoms at baseline has been shown to predict development of AD during a 7-year period, with risk of AD increasing by 20% with each additional depressive symptom. 18 Furthermore, two other studies reported that more-severe depressive symptoms, 14 or a clinical diagnosis of depression, 15 increased risk of dementia almost threefold as much as 5 years after the depression diagnosis. Finally, our longitudinal study on depression and risk of dementia included a separate diagnosis for dysthymia or minor depression. We reported that severity of depression is an important factor, 16 as patients diagnosed with dysthymia or depression had a more than twofold increased risk of dementia diagnosis over 7 years compared with those without dysthymia or depression. A 'dose effect' was observed, with depression carrying a higher dementia risk than dysthymia.
Certain groups of individuals may be at an increased risk of dementia associated with depression. Men, but not women, with depressive symptoms had an almost fourfold increased likelihood of developing dementia over an 8-year period in one longitudinal study. 19 Interestingly, another longitudinal study found that depression was associated with a sevenfold increased risk of dementia over a 6-year period, but only when con sidered together with apolipoprotein E ε4 status (a genetic risk factor for AD). 20 A third study demonstrated that among older adults (65-84 years) with >8 years of education, those with depressed mood had nearly fourfold increased odds of developing AD during a 4-year period of follow-up compared with those without depressed mood. 21 These studies suggest that late-life depression may be an early symptom or subclinical expression of dementia that is more overt in certain groups and, perhaps, observed at the time of more-advanced AD.
Results from the two cross-sectional studies are conflicting on whether late-life depression and dementia are indeed associated. One of these studies reported that indivi duals with depression were 20% and 40% more likely to be diagnosed with VaD and AD, respectively. 24 The other cross-sectional (case-control) study showed a marginal association between depression and all-cause dementia, but the study was underpowered. 25 In agreement with the former cross-sectional study, a prospective nested case-control study found a twofold increased likelihood of incident VaD in patients with a history of depression, 17 suggesting that results may be consistent across AD and VaD.
Two separate meta-analyses concluded that depression increased the risk of dementia twofold. 26, 27 These metaanalyses mostly included case-control studies from before the year 2000, but the pooled findings suggest that late-life depression is associated with subsequent dementia, even if the effect is not robust across all individual studies.
Current research supports an association between latelife depression and risk of dementia, although inconsistencies across individual studies exist. Discrepancies may be attributable to methodological differences (for example, sampling procedures and attrition rates, definition and operationalization of depression), potential cultural differences between the various studies (locations included the USA, Canada, Israel, Netherlands, France, Denmark, Turkey, China and the UK), or subpopulation differences (for example, inclusion of veterans, clergy, Japanese American men). Furthermore, because of the timing of many of these studies in late life, whether depression or depressive symptoms are a prodromal phase of dementia, a consequence of the onset of AD or risk factor for dementia cannot be distinguished. In fact, the variability of the duration of follow-up (0-17 years) and unknown frequency or duration of depressive episodes may explain the heterogeneity of the findings.
Earlier-life depression and dementia risk Several studies, conducted over the past 8 years, including case-control and prospective cohort studies (Table 2) , have investigated the risk of dementia associated with earlier-life depression (typically defined as depression or depressive symptoms occurring before age 60 years). Both historical measures of depression diag nosis and standard instruments for symptoms or diag nosis of depression have been used. Together, these studies suggest that earlier-life, or early onset of, depression is markedly associated with risk of developing dementia.
Four of the five studies in Table 2 were longitudinal, and the findings suggest that early onset of depression, as well as longer duration and higher frequency of depression, were associated with a twofold to fourfold increased risk of developing dementia. One longi tudinal study, which found an almost fourfold increased risk of AD among individuals with early-onset depression (before age 60 years), but not late-onset depression, seemed underpowered (only 486 participants were included in the study, and were followed for an average of 6 years). 28 Following a large number of individuals over many years can be challenging and costly but, nevertheless, the other three longitudinal studies had larger sample sizes (up to 13,535 study participants) and longer follow-up times (up to 51 years). Both the Dal Forno et al. 29 and Dotson et al. 30 studies used innovative methods to assess depressive symptoms as time-dependent covariates. Dal Forno and colleagues 29 used a lag-time approach for depression assessment-that is, depression analyzed at multiple preset time lengths (2, 4 and 6 year intervals) before dementia onset-in their analyses to better address temporality and direction of the depression-dementia association, 29 while Dotson and colleagues 30 measured recurrent depression over five decades.The results of the first study suggested that prodromal dementia was not the cause of the association, because the twofold increase in risk of dementia associated with depression remained intact when the lag between detection of symptoms and diagnosis of dementia was ≥4 years; however, this result was found only among men. The second study demonstrated a strong association between the number of depressive episodes (that is, recurrent depression) and risk of dementia over a median follow-up time of 24 years, suggesting a dose-dependent relationship between cumulative depression episodes and risk of dementia.
The fourth longitudinal study examined the association of earlier-life depression with different subtypes of dementia, including VaD and AD, and compared risk of dementia in people with depressive symptoms at midlife and late life. 31 Barnes and co-workers 31 concluded that mid-life (aged 40-50 years) depressive symptoms were associated with the risk of AD and VaD. Risk of AD was approximately doubled in individuals with depressive symptoms in late life (aged ≥60 years), either alone or in combination with mid-life symptoms, and the risk of VaD was more than tripled in those with both mid-life and late-life depressive symptoms. These findings suggest that depression over the lifetime is associated with an increased risk of VaD, but risk of AD was more dependent on late-life experience.
The one cross-sectional (case-control) study suggests that history of depression even 25 years before AD onset is associated with an almost twofold increase in the likelihood of developing AD, 32 whereas depressive symptoms within the first year before onset of AD were associated with an almost fivefold increased AD risk. This finding could be explained by an overlap of symptomatology when depressive symptoms are assessed close in time to the dementia diagnosis. In addition, despite the study's large sample size (1,953 individuals with AD and 2,093 un affected relatives as controls) and ability to assess multiple years of depression symptoms before AD onset, the accuracy of the results may be questionable owing to recall bias; for example, informants of patients with AD may be more likely to recall events in line with their pr econceptions about potential links.
In summary, earlier-life depression has consistently been found to be a risk factor for, and seems unlikely to be a prodrome of, dementia. A strength of the above-mentioned studies, unlike the studies of late-life depression, is their relative homogeneity; four out of five are samples from the US population, all measured depressive symptoms with similar questions and cut-offs, and all had substantial follow-up time (as much as 51 years). Further longitudinal studies over the lifespan, however, are necessary to fully understand the relationship between depression and depressive sy mptoms and risk of developing dementia in late life.
Potential mechanisms
The most prominent mechanisms that may link depression and dementia are presented in Figure 1 . Each hypothesized pathway represents a mechanistic link between depressionrelated processes and dementia-specific neuropathology, including vascular disease; alterations in glucocorticoid steroid levels and hippocampal atrophy; increased deposition of amyloid-β (Aβ); inflammatory changes; and deficits of nerve growth factors or neurotrophins.
Vascular disease
Evidence that vascular disease is the underlying link between depression and dementia is strong. This link is largely grounded in the 'vascular depression hypothesis' , 33, 34 which states that cerebrovascular disease predisposes to, precipitates or perpetuates some geriatric depressive syndromes. 35, 36 A number of studies have reported that vascular lesions as well as structural brain changes may contribute to depression in late life. [37] [38] [39] [40] Whether vascular disease or vascular lesions contribute to depression or result from depression is debatable, as each condition is associated with an increased risk of developing the other. 41 The pathway from vascular disease to depression and then dementia is probably not sequential (Figure 1 ). Prior depression is related to subsequent vascular disease through multiple proposed mechanisms, including behavioral conditions (for example, smoking, inactivity), hypothalamic-pituitary-adrenal (HPA)-axis dysregulation and elevated cortisol levels associated with the metabolic syndrome, disruption of normal endothelial function and development of hypertension, and proinflammatory cytokines. 42 In particular, depression increases the risk of first-ever myocardial infarction and stroke. 43 In addition, the evidence that vascular disease promotes development of depression is strong. Risk of depression is substantially increased after myocardial infarction or stroke; 41 MRI studies have shown robust associations between ischemic brain lesions and depression or depressive symptoms in older adults. 44, 45 Longitudinal studies provide evidence that large cortical white matter lesions and severe grade of subcortical white matter are substantial risk factors for develop ing depressive symptoms. 45 These white matter changes have been found to predate and predict oc currence of late-life depression. 45, 46 In further support of the 'vascular depression-dementia hypothesis' , vascular disease has been shown to contribute to the clinical manifestation of dementia symptoms. 47, 48 Ischemic damage, largely in the frontostriatal brain regions, may lead to substantial cognitive deficits. 49 Finally, executive function deficits, psychomotor slowing, and resistance to treatment, all of which are common in late-life depression, could be explained by ischemic damage to frontostriatal brain regions. 42, 49, 50 Ischemic structural changes in the brain could, therefore, be a common etiological factor in both depression and the related cognitive impairment.
Cortisol-hippocampal pathway
Increased cortisol production leading to atrophy of the hippo campus is another of the proposed primary links between depression and dementia. In this pathway, depression and depressive symptoms activate the HPA axis and increase glucocorticoid production, which may in turn damage the hippocampus and result in do wnregulation of glucocorticoid receptors (Figure 1 ). The net effect is impaired negative feedback to the HPA axis and chronic elevation of adrenal glucocorticoid levels (or 'glucocorticoid cascade' 51 ), ultimately resulting in a vicious circle of hippo campal atrophy and cognitive deficits. 42, 52 Impairment in glucocorticoid metabolism (for example, increased cortisol bioavailability) has been documented in patients with depression 53 and patients with dementia. 54 In addition, atrophy of the hippocampus is one of the early brain changes in AD, 55 and reduced hippocampal volume has been found in patients with depression. [56] [57] [58] Research investigating the cortisol-hippocampal link to depression and dementia has mainly been confined to animal studies that involve response to stress. High-stress conditions or exogenous gluco corticoids can cause hippocampal neuronal damage 59 and memory impairment, 60 and hippocampal damage progresses over a lifetime of stress or glucocorticoid excess. 61 As stressful life events are highly related to depressive episodes in humans [62] [63] [64] and the HPA axis is hyperactive in depression, 65 ,66 a similar cycle may exist in humans.
Some studies have found that loss of hippocampal volume increases the risk of cognitive decline 67, 68 and even dementia 69 in adults with depression, but these findings are conflicting. 28, 70 In one study, history of depression was not associated with hippocampal volumes at baseline, and these volumes did not correlate with the increased risk of AD associated with prior depression, 28 which implies that the effect of depression is not mediated through hippocampal atrophy. By contrast, reductions in hippocampal volume have been found consistently among individuals with recurrent depression and long duration of illness (that is, increased duration of depression is correlated with increased loss of hippocampal volume), 58, 71, 72 providing support for involvement of the cortisol-hippocampal pathway in depression and dementia risk.
Even if the relationship between depression and hippocampal atrophy is confirmed, evidence that this association is mediated by increased cortisol levels is inconsistent. 56, 58 Additionally, in other studies, hippo campal atrophy was associated with inflammatory changes and deficits of nerve growth factors in patients with depression and other psychi atric disorders. [73] [74] [75] This finding suggests that mecha nisms other than-or in addition to-elevated cortisol levels may be important, but further research is ne cessary to elucidate these pathways.
Amyloid-β plaque formation Like hippocampal atrophy, Aβ plaques in the brain are a diagnostic feature of AD. Both Aβ and tau protein accumulate in AD and are the main constituents of neuritic plaques and neurofibrillary tangles, respectively. 76 Interestingly, studies have shown that both plaques and tangles accumulate in higher numbers in the hippocampus of AD patients with depression than in those without depression. 77, 78 Furthermore, the literature supports a role for Aβ as a primary factor in promoting the cascade of events that leads to neuronal death and AD. 79, 80 Thus, a possible mechanism linking depression to AD involves Aβ plaque formation; however, the association is controversi al and poorly understood.
One hypothesized pathway linking depression and Aβ entails increased Aβ production initiated by a stress response associated with depression and glucocorticoid levels. 11, 52 This hypothesis has primarily been suggested by results from animal models of AD, in which administration of stress-level glucocorticoids promotes Aβ formation by increasing steady-state levels of Aβ precursor protein and β-secretase 1 (also known as β-site amyloid precursor protein cleaving enzyme 1 or BACE1; important in the formation of Aβ proteins). 81 In addition, depression might influence Aβ accumulation through direct interaction with the amyloidogenic processing early in AD, a process that may be linked to the serotonergic system. 52, 82, 83 Finally, work from the past few years has shown that plasma Aβ concentrations in patients with depression are related to cognitive impairment. A type of amyloidassociated depression (depression with a high ratio of plasma Aβ 40 to Aβ 42 ) has been linked with impairment in memory, visuospatial abilities, and executive function. 84 Amyloid-associated depression may represent a preclinical or prodromal depression of AD or a path to AD, although more research is necessary in this area.
Inflammatory changes
Research suggests that chronic inflammation has a central role in the pathophysiology of both depression and dementia. 73, 85, 86 Two potential pathways that involve inflammatory changes within the CNS link depression and dementia. First, the increase in levels of cytokinesfor example, interleukin (IL)-6 and tumor necrosis factor (TNF)-found in depression may lead to a decrease in anti-inflammatory and immunosuppressant regulation, an increase in pro inflammatory changes within the CNS and, ultimately, cognitive deficits and dementia. 87, 88 Second, proinflammatory cytokines (such as IL-6 and TNF) interfere with 5-hydroxytryptamine metabolism, and reduce both sy naptic plasticity and hippocampal neurogenesis.
11,73
The inflammatory process is potentially intricately linked with multiple neurodegenerative pathways for depression, as well as numerous proinflammatory cytokines. According to in vitro and in vivo studies, Aβ activates microglia to release proinflammatory cyto kines, 89 and microglial activation has been found in patients with mild cognitive impairment. 90 Thus, chronic inflammation may explain why a history of depression can promote development of dementia; however, more studies are neces sary to elucidate and confirm this link, as the role of microglial cells and inflammation has been challenged in a 2009 study. 91 Nerve growth factors Another proposed link between depression and dementia is a decrease in the levels and activities of neurotrophic factors, such as brain-derived neurotrophic factor (BDNF; Figure 1) . 11 This neurotrophin is part of a class of growth factors that are necessary for maintenance of neuronal health and modulation of synaptic plasticity. 92 Impairment in BDNF signaling has been detected in stress-induced animal models of depression 93 and individuals with depression, 75, 94 as well as being exhibited in patients with AD. 95, 96 In fact, studies of both depressed and AD patients have demonstrated decreased messenger RNA levels of BDNF in the hippocampus; 52, 75 however, data on this subject is controversial. 97, 98 Given these findings and the key role of BDNF in regulating hippocampal plasticity, BDNF is presumed to be important for integrity of the hippo campus and maintenance of cognition. Other important neurotrophic factors include transforming growth factor-β1, insulin-like growth factor I, and vascular endothelial growth factor. 99 
Treatment and management implications
Currently, 35.6 million individuals worldwide have dementia, and the associated costs of this disease were more than US$600 billion in 2010. 100 The prevalence of dementia is projected to increase to 65.7 million by 2030, with associated costs expected to rise by 85%. 100 Thus, delaying dementia onset could prevent millions of individuals from getting this disease and save billions of dollars in associated health-care costs.
Although research to date has not resolved whether depression is a prodrome of, or risk factor for, dementia, the link between depression and risk of dementia as a whole suggests a strong association. If a patient presents with depression or depressive symptoms, particularly in late life, then screening for cognitive deficits should become part of the patient's management or clinical care. In addition, studies on earlier-life depression suggest that older adults with a history of previous depression should be closely monitored for both recurrent depression and cognitive decline. Some studies have shown that treatment of depression (involving pharmacological, be havioral or other modalities) in elderly patients improves cognition, leading to improved memory and other aspects of cognitive performance, [101] [102] [103] [104] and may reduce patho physiological alterations related to dementia. 71, [105] [106] [107] Other studies, however, have shown that cognitive deficits either persist or still ensue after successful treatment for depression. [108] [109] [110] Considering that the risk of developing AD more than doubles in adults with co-occurring depression and mild cognitive impairment compared with mild cognitive impairment alone, 111 monitoring and reducing cognitive decline in depressed individuals with executive, as well as memory, im pairment is imperative.
An alternative strategy to improving the course of cognitive decline with depression interventions is an integrated treatment approach. A 2008 pilot study in this area showed promising results; addition of a cholinesterase inhibitor after antidepressant medication treatment in depressed elderly patients who also had cognitive impairment resulted in marked improvements in memory. 112 Another approach is to combine antidepressants with behavioral interventions that might protect against cognitive decline (for example, exercise or cardiovascular risk modification). A combined treatment approach of antidepressants, cholinesterase inhibitors, vitamins, and diet, lifestyle and exercise modifications has been found to prevent progression of cognitive decline over 24 months and improve memory and frontal lobe functions. 113 Testing of the efficacy and effectiveness of such interventions is in its infancy, but these integrated strategies nevertheless hold great promise. Future studies should thus continue to examine the implications of depression modification in clinical trials, focusing on whether simultaneous or sub sequent interventions have additive or multiplicative effects on cognition.
On a related topic, the efficacy and effectiveness of treating depression and reducing depressive symptoms in patients with AD is controversial. Although experts recommend treating depression in AD, 114 findings from controlled pharmacological trials are inconclusive. Some studies have shown that antidepressant treatment reduces depressive symptoms, 115 but most studies have shown no difference between placebo and standard antidepressant medications in patients with depression and AD. [116] [117] [118] This finding indicates a potentially different neuro pathology of depressive symptoms in the context of AD. For example, evidence that increased loss of noradrenaline-producing neurons in the locus co eruleus is associated with cooccurring depression and AD is consistent, [119] [120] [121] which implicates the nor adrenergic system as another pathway linking depression to dementia, and as a possible target for intervention. More work is necessary in this area, as it is essential to reduce neuropsychiatric disturbances and improve quality of life in patients with AD.
Conclusions
This Review highlights the current research on depression and risk of dementia. These findings emphasize the importance of closely monitoring patients with depression for development of dementia. Furthermore, studies of potential mechanisms linking depression to AD and VaD are warranted so that intervention, prevention, and health-care needs can be targeted. In particular, future research should include a life-course approach to the study of depression and dementia. Earlier-life depression has been shown to be an important risk factor for dementia, but whether it is a true risk factor for development of dementia or whether a third factor causes depression and dementia is still unknown. In addition, the nature of the association between late-life depression and dementia is unclear. A life-course approach to the study of depression and risk of developing dementia would, therefore, be highly informative.
In summary, the population is rapidly aging and the risk of dementia is projected to quadruple by 2050. 122 Intervention into a modifiable risk factor, such as depression, and studying its effect on reducing the risk of dementia is, therefore, imperative. The underlying pathway linking depression to dementia is multifactorial, and the proposed mechanisms are probably not mutually exclusive, which suggests a combined regimen as the most promising treatment approach for alleviating dementia risk.
Review criteria
Recent literature on late-life and earlier-life depression and risk of developing dementia (clinical diagnosis based on standard criteria and a control group for comparison) were examined for this Review. Studies were reviewed if they were published in 2000 or later, if they measured late-life or earlier-life depression and late-life dementia, and if they were published in English. Articles were selected on the basis of the authors' personal knowledge and searches of the PubMed database using the terms "depression", "depressive symptoms" and "major depression" in combination with the terms "dementia" or "Alzheimer's disease" or "vascular dementia". Reference lists of the identified papers were examined for further leads. The final selection was based on relevance, as judged by the authors.
